Donald Rubenstein, MD
Clinical Cardiac Electrophysiology · West Orange, NJNPI 1912966276
Payments from drug & device makers
Across 496 payments — averaging $95.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$24K
- Abbott$17K
- Boston Scientific$2K
- Pfizer$809
- Johnson & Johnson$604
- Merck$479
- plus $3K from 31 others
What the payments were for
- Travel & lodging$1,09513%
- Food & beverage$7,23687%
- Education$80%
- Other$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 124 | $24,083 |
| Abbott | 34 | $16,760 |
| Boston Scientific | 40 | $2,191 |
| Pfizer | 68 | $809 |
| Johnson & Johnson | 46 | $604 |
| Merck | 31 | $479 |
| Amgen | 23 | $326 |
| E.r. Squibb & Sons, L.L.C. | 19 | $281 |
| Amarin Pharma, Inc. | 18 | $236 |
| Novo Nordisk | 9 | $148 |
| Sanofi-aventis U.S. LLC | 7 | $128 |
| Heartflow, Inc. | 3 | $125 |
| Boehringer Ingelheim | 8 | $118 |
| Kestra Medical Technology Services, Inc. | 5 | $115 |
| Bayer | 5 | $103 |
| AstraZeneca | 7 | $102 |
| Lundbeck LLC | 7 | $101 |
| Irhythm Technologies, Inc. | 5 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $77 |
| Philips North America LLC | 4 | $76 |
| Cvrx, Inc. | 4 | $75 |
| Impulse Dynamics (USA) Inc. | 2 | $59 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Itamar Medical Inc | 1 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| Altathera Pharmaceuticals LLC | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Inari Medical, Inc. | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Acarix USA Inc. | 1 | $13 |
| Welch Allyn | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM$1,260
- GENERAL - THERAPIES$114
How this compares
$47,506 in reported general payments places this provider in the 65th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
See all clinical cardiac electrophysiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 404 | $438,114 |
| XareltoRivaroxaban | 116 | $123,897 |
| EntrestoSacubitril/Valsartan | 79 | $98,991 |
| MultaqDronedarone Hcl | 20 | $41,862 |
| JardianceEmpagliflozin | 17 | $17,534 |
| BrilintaTicagrelor | 24 | $12,381 |
| Metoprolol Succinate | 688 | $9,935 |
| Flecainide Acetate | 132 | $5,713 |
| Atorvastatin Calcium | 375 | $4,314 |
| Rosuvastatin Calcium | 258 | $4,108 |
| Ezetimibe | 118 | $3,394 |
| Amlodipine Besylate | 431 | $3,110 |
| Midodrine Hcl | 39 | $2,952 |
| Amiodarone Hcl | 167 | $2,812 |
| Losartan Potassium | 242 | $2,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $809 | $438,114404 claims |
| Johnson & JohnsonXarelto | $604 | $123,897116 claims |
| NovartisEntresto | $24,083 | $98,99179 claims |
| Sanofi-aventis U.S. LLCMultaq | $128 | $41,86220 claims |
| Boehringer IngelheimJardiance | $118 | $17,53417 claims |
| AstraZenecaBrilinta | $102 | $12,38124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
Other clinical cardiac electrophysiology in West Orange
- Marc RoelkeWest Orange$146K
- David DobeshWest Orange$96K
- Edward KoganWest Orange$24K
- Suneet MittalParamus$2.3M
- Benjamin D SouzaCherry Hill$1.2M
- George MarkHaddon Heights$935K
- Sanjeev SaksenaWarren$911K
- Darius SholevarCherry Hill$843K
- Jonathan SteinbergRidgewood$490K
- Emad AzizNewark$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.